Joseph Araujo
Founder presso MINDSET PHARMA INC.
Patrimonio netto: 66 600 $ in data 31/10/2023
Profilo
Joseph Araujo is the founder of CanCog Technologies, Inc. (founded in 2002), Karyopharm Therapeutics, Inc. (founded in 2008), and Mindset Pharma, Inc. (founded in 2019), where he held various executive titles.
He currently holds director positions at Vivocore, Inc. and Transpharmation Ltd.
He previously served as President & Chief Executive Officer at InterVivo Solutions, Inc. from 2010 to 2023.
Mr. Araujo received an undergraduate degree from the University of Toronto.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
MINDSET PHARMA INC.
0.09% | 31/08/2023 | 90 000 ( 0.09% ) | 66 600 $ | 31/10/2023 |
Posizioni attive di Joseph Araujo
Società | Posizione | Inizio |
---|---|---|
MINDSET PHARMA INC. | Founder | 07/10/2019 |
CanCog Technologies, Inc.
CanCog Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services CanCog Technologies, Inc. operates as a contract research organization providing non-invasive research and development services in the companion animal market. The firm's services include food intake, cognitive assessment, activity and movement, imaging and special technologies. The company was founded by Norton William Milgram and David R. Stevens in 2002 and is headquartered in Toronto, Canada. | Chief Executive Officer | 01/03/2022 |
Vivocore, Inc.
Vivocore, Inc. Miscellaneous Commercial ServicesCommercial Services Vivocore, Inc. is a non-invasive research and Canadian development company. | Director/Board Member | - |
Transpharmation Ltd.
Transpharmation Ltd. BiotechnologyHealth Technology Part of Vivocore, Inc., Transpharmation Ltd. is a contract research organization. The private company is based in London, UK. The British company was founded in 2010 by Neil Upton, Mark Steven Duxon. Mark Steven Duxon has been the CEO since 2010. Transpharmation was acquired by Vivocore, Inc. on February 07, 2022. | Director/Board Member | 16/09/2021 |
Precedenti posizioni note di Joseph Araujo
Società | Posizione | Fine |
---|---|---|
InterVivo Solutions, Inc.
InterVivo Solutions, Inc. Miscellaneous Commercial ServicesCommercial Services InterVivo Solutions, Inc. offers high-quality, translational drug discovery services to accelerate drug discovery programs to the clinic. The Canadian company provides a carefully selected array of neuroscience models and experiments to help propel new drugs forward through the development track. The private company's designed pharmacokinetics studies provide reliable data ensuring faster screening, selection, and development of lead candidates. The company has expertise in neurological disease models and laboratory testing capabilities to support emerging research. The company welcomes inquiries for novel approaches for model and bioanalytical development. Additionally, Transpharmation, a preclinical neuroscience CRO, relays a number of natural models of disease via the largest world-class canine colony in the industry. InterVivo Solutions can assist in discovering how they can help. | Chief Executive Officer | 01/03/2023 |
KARYOPHARM THERAPEUTICS INC. | Founder | 01/09/2010 |
Formazione di Joseph Araujo
University of Toronto | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
KARYOPHARM THERAPEUTICS INC. | Health Technology |
MINDSET PHARMA INC. | Health Technology |
Aziende private | 4 |
---|---|
CanCog Technologies, Inc.
CanCog Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services CanCog Technologies, Inc. operates as a contract research organization providing non-invasive research and development services in the companion animal market. The firm's services include food intake, cognitive assessment, activity and movement, imaging and special technologies. The company was founded by Norton William Milgram and David R. Stevens in 2002 and is headquartered in Toronto, Canada. | Commercial Services |
InterVivo Solutions, Inc.
InterVivo Solutions, Inc. Miscellaneous Commercial ServicesCommercial Services InterVivo Solutions, Inc. offers high-quality, translational drug discovery services to accelerate drug discovery programs to the clinic. The Canadian company provides a carefully selected array of neuroscience models and experiments to help propel new drugs forward through the development track. The private company's designed pharmacokinetics studies provide reliable data ensuring faster screening, selection, and development of lead candidates. The company has expertise in neurological disease models and laboratory testing capabilities to support emerging research. The company welcomes inquiries for novel approaches for model and bioanalytical development. Additionally, Transpharmation, a preclinical neuroscience CRO, relays a number of natural models of disease via the largest world-class canine colony in the industry. InterVivo Solutions can assist in discovering how they can help. | Commercial Services |
Vivocore, Inc.
Vivocore, Inc. Miscellaneous Commercial ServicesCommercial Services Vivocore, Inc. is a non-invasive research and Canadian development company. | Commercial Services |
Transpharmation Ltd.
Transpharmation Ltd. BiotechnologyHealth Technology Part of Vivocore, Inc., Transpharmation Ltd. is a contract research organization. The private company is based in London, UK. The British company was founded in 2010 by Neil Upton, Mark Steven Duxon. Mark Steven Duxon has been the CEO since 2010. Transpharmation was acquired by Vivocore, Inc. on February 07, 2022. | Health Technology |
- Borsa valori
- Insiders
- Joseph Araujo